Asia Pacific
Refine Search
Biotechnology
South Korea’s Alteogen has signed an exclusive licensing agreement with Japanese pharmaceutical company Daiichi Sankyo for its human hyaluronidase, ALT-B4. 9 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Biotechnology
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on Thursday. 8 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Photocure, a Norway-based bladder cancer-focused company, has announced that Jiangsu Yahong Meditech, the parent company of its partner Asieris Pharmaceuticals, has received marketing authorization for Hexvix (hexaminolevulinate) in China. 5 November 2024
Biotechnology
Japan’s Nxera Pharma – formerly known as Sosei – and Antiverse, a UK techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). 5 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sugemalimab (trade name Eqjubi) to treat adult patients with a type of cancer called non-small cell lung cancer (NSCLC ). 31 October 2024
Pharmaceutical
Japanese pharma major Takeda today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. 31 October 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
Takeda has release positive interim results from a Phase III-enabling proof-of-concept study for mezagitamab (TAK-079), a potential best-in-class anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN). 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Pharmaceutical
Corxel Pharmaceuticals and LENZ Therapeutics have reported encouraging topline results from a Phase III trial in China testing LENZ’s aceclidine-based eye drop, LNZ100. 29 October 2024
Pharmaceutical
Japanese drugmaker Shionogi saw its shares rise 2.3% to 2,173 yen today after it released positive research findings. 29 October 2024
Biotechnology
Yongyin-based biopharma company GC Biopharma has announced a partnership with Novelty Nobility for the joint development of a new treatment for geographic atrophy (GA). 28 October 2024
Pharmaceutical
Japanese drugmaker Astellas Pharma revealed it has decided to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution (ACP). 28 October 2024
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Pharmaceutical
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Pharmaceutical
The European Society for Medical Oncology (ESMO) is launching Rare Cancers Asia (RCA). 21 November 2018
Biotechnology
In the latest example of biotech belying the trade tensions between political leaders, Chinese and US investors have joined in the financing of an oncology-focused biopharma based in China. 21 November 2018
Biotechnology
The China National Medical Products Administration (NMPA) has approved Vemlidy (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35kg). 19 November 2018
Pharmaceutical
French drugmaker Sanofi has signalled its intention to introduce six innovative drugs and vaccines to the Chinese market “as early as possible.” 14 November 2018
Biotechnology
Shares in Samsung BioLogics climbed 9% on Tuesday, as concerns over the firm being delisted due to accounting irregularities appeared to subside. 13 November 2018
Biotechnology
Japanese pharma major Daiichi Sankyo says that the European Medicines Agency has validated for review and granted accelerated assessment to the Marketing Authorization Application (MAA) for quizartinib for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) which is FLT3-ITD positive. 6 November 2018
article
The one-two punch that guarantees success in Japan’s pharma market is a new drug and good people to execute its development and marketing. One without the other is like a kiss without a squeeze, writes long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer in his exclusive column for The Pharma Letter. 6 November 2018
Biotechnology
Japanese drugmaker Kissei Pharmaceutical has acquired exclusive rights to develop and commercialize Tavalisse (fostamatinib disodium) in all current and potential indications in Japan, China, Taiwan and the Republic of Korea. 29 October 2018
Generics
Aiming to curb unhealthy practices in the pharmaceutical sector, the Competition Commission of India (CCI) has identified key issues hurting the sector and is looking at ways to better regulate it. With branded generics dominating the Indian drug market, the CCI has called for regulation to allow consumers to buy standardized consumables from the open market, reports The Pharma Letter’s India correspondent. 29 October 2018
Pharmaceutical
The recent pharma regulatory reforms by China are expected to provide opportunities for both domestic as well as foreign contract manufacturing organizations (CMOs). 26 October 2018
Biotechnology
In its initial public offering (IPO) on the Hong Kong Stock Exchange, China’s Innovent Biologics has reportedly sold around $421 million worth of shares priced at the top end of estimates, at about $1.78 per share. 25 October 2018
Pharmaceutical
Chugai Pharmaceutical has concluded a collaborative research agreement with privately held fellow Japanese biopharmaceutical company Anaeropharma Science concerning the creation of novel oncology drugs utilizing characteristic features of Bifidobacterium longum through Anaeropharma's proprietary platform technology, "in situ Delivery and Production System" (i-DPS). 22 October 2018
Pharmaceutical
Daiichi Sankyo has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labor and Welfare (MHLW) for marketing approval of quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). 17 October 2018
Biotechnology
Chinese biotech Innovent Biologics wants to raise $422 million in an initial public offering (IPO) to take forward its monoclonal antibodies and other biologics in oncology, ophthalmology, autoimmune, and cardiovascular diseases. 16 October 2018
Pharmaceutical
Shanghai-listed Zhejiang Huahai Pharmaceutical has been placed under close supervision by European authorities, after an inspection uncovered “quality management weaknesses” at the company’s Chuannan site in Linhai, China. 16 October 2018
Biotechnology
The firm that calls itself the leading oncology company in Japan strengthened its position on Wednesday with the approval of its breast cancer drug in a new indication in the Asian country. 11 October 2018
Pharmaceutical
The three Japanese drugmakers that launched a program a year ago to discover new treatments using a drug-repositioning compound library have started a second recruitment round to find new researchers. 10 October 2018
Generics
US drugmaker CASI Pharmaceuticals has appointed Larry Zhang president of its Chinese subsidiary. 2 October 2018
Pharmaceutical
Japanese pharma major Astellas Pharma today revealed that it has submitted a New Drug Application (NDA) for marketing approval in Japan of roxadustat for the treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis. 1 October 2018
Biotechnology
Legend Biotech, a subsidiary of reagents services provider Genscript Biotech Corporation, regained some of Thursday’s stock market losses on Friday. 1 October 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze